Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group

Head and Neck

Volumn 35, Issue 7, 2013, Pages 942-948

  Gilbert, Jill ^a   Lee, Ju Whei ^b   Argiris, Athanassios ^c,h   Haigentz Jr , Missak ^d   Feldman, Lawrence Eric ^e   Jang, Minyoung ^f   Arun, Pattatheyil ^f   Van Waes, Carter ^f   Forastiere, Arlene A ^g  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

bortezomib; chemotherapy; head and neck cancer; irinotecan; phase II

Indexed keywords

BORTEZOMIB; CXCL3 CHEMOKINE; DEXAMETHASONE; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; IRINOTECAN; SCATTER FACTOR; SEROTONIN 3 ANTAGONIST; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARM DISEASE; ARTICLE; ASPIRATION; BLOODSTREAM INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CAROTID ARTERY INJURY; CONSTIPATION; CONTROLLED STUDY; CYTOKINE RESPONSE; DEATH; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; FEVER; FOREIGN BODY REACTION; GLOMERULUS FILTRATION RATE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INSOMNIA; LEUKOCYTE; LUNG INFECTION; LUNG INFILTRATE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STOMACH HEMORRHAGE; THROMBOCYTE; TRACHEITIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CYTOKINES; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B; PYRAZINES; TREATMENT OUTCOME;

EID: 84879420939     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23046     Document Type: Article

References (18)

1. Langer CI,. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 2008; 112: 2635-2645.
2. Gibson MK, Li Y, Murphy B, et al. Randomized Phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-3567.
3. Pfister DG, Ang KK, Brizel DM, et al. Head and Neck Cancers. J Natl Compr Cancer Netw 2011; 9: 596-650.
4. Van Waes C,. Nuclear factor-kappaB in development, prevention and therapy of cancer. Clin Cancer Res 2007; 13: 1076-1082.
5. Cusack JC, Liu R, Houston Am, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535-3540.
6. Allen CT, Ricker JL, Chen Z, Van Waes C,. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 959-971.
7. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF,. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as resistance mechanism to camptothecin in tumor cells. Cancer Res 2001; 61: 5926-5932.
8. Murphy BA, Cmelak A, Burkey B, et al. Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology 2001; 15: 47-52.
9. Gilbert J, Cmelak A, Shyr Y, et al. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer 2008; 113: 186-192.
10. Wang J, Sampath A, Raychaudhuri P, Bachi S,. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 2001: 4740-4749.
11. Argiris A, Buchanan A, Brockstein B, et al. Docetaxel and iriontecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4504-4513.
12. Allen C, Duffy S, Teknos T, et al. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007; 13: 182-190.
13. Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C,. Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 2009; 15: 5974-5984.
14. Chen Z, Ricker JL, Malhotra PS, et al. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-I related mechanisms. Mol Cancer Ther 2008; 7: 1949-1960.
15. Sloss CM, Wang F, Liu R, et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 2008; 14: 5116-5123.
16. Chung CH, Aulino J, Muldowney NJ, et al. Nuclear factor-kappa B pathway and response in bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010; 21: 864-870.
17. Argiris A, Duffy A, Kummar S, et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab and radiotherapy for head and neck cancer. Clin Cancer Res 2011; 17: 5755-5764.
18. Li C, Zang Y, Sen M, Leeman-Neill RJ, et al. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther 2009; 8: 2211-20.